Despite the fact that several studies have been published regarding the prognostic factors of
neuroendocrine tumors (NETs), there are some cases in which available data are not …

This study was performed to investigate the role of 68Ga-DOTANOC SUVmax as a potential
prognostic factor in patients with pancreatic neuroendocrine tumor (pNET). Methods: Among …

We aimed to evaluate 68Ga-DOTATATE PET/CT for the early prediction of time to
progression and clinical outcome after a first cycle of peptide receptor radionuclide treatment …

Purpose To determine the prognostic value of 68 Ga-DOTANOC PET/CT in patients with
well-differentiated neuroendocrine tumor (NET), and to compare the prognostic value with …

Several authors reported the superiority of 68Ga-DOTANOC PET/CT to conventional
imaging (CI) for the assessment of neuroendocrine tumors (NET). However, the detection of …

The aim of this study was to determine whether quantitative PET parameters on baseline
68Ga-DOTATATE PET/CT and interim PET (iPET) performed before the second cycle of …

Purpose The aim of this study was to assess the diagnostic performance of simultaneous
whole-body 68 Ga-DOTANOC PET/MRI compared with 68 Ga-DOTANOC PET/CT for …

Somatostatin receptor PET tracers such as [68Ga-DOTA, 1-Nal3]-octreotide (68Ga-
DOTANOC) and [68Ga-DOTA, Tyr3]-octreotate (68Ga-DOTATATE) have shown promising …

Abstract Purpose Neuroendocrine tumours (NETs) can be imaged with scintigraphy using
radiolabelled somatostatin analogues. The aim of our study was to compare the value of 68 …

Objective The objective of this study was to evaluate the predictive value of 68 Ga-
DOTANOC PET/CT in patients with suspected neuroendocrine tumor (NET). Methods Data …